Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.71 |
| ▸ | SYK | P43405 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 11/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 9/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 3/20 | 0.58 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.55 |
| ▸ | TUBB | P07437 | 2/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31355261 | 1.00 | SALL4 (0.71) | SALL4SYKGAAKDM4ELMNA | |
| SCHEMBL31355335 | 0.94 | SALL4 (0.69) | SALL4SYKGAAKDM4ELMNA | |
| SCHEMBL31355390 | 0.91 | SYK (0.81) | SALL4SYKGAAKDM4ELMNA | |
| SCHEMBL31355339 | 0.90 | SYK (0.85) | SALL4SYKGAAKDM4ELMNA | |
| SCHEMBL31355280 | 0.90 | GAA (0.67) | SALL4SYKGAAKDM4ELMNA | |
| SCHEMBL26908187 | 0.89 | GAA (0.71) | SALL4SYKGAAKDM4ELMNA | |
| SCHEMBL31355374 | 0.88 | SYK (0.69) | SALL4SYKGAAKDM4ELMNA | |
| SCHEMBL31355274 | 0.87 | SYK (0.66) | SALL4SYKGAAKDM4ELMNA | |
| SCHEMBL31355404 | 0.86 | MAPT (0.77) | SALL4SYKGAAKDM4ELMNA | |
| SCHEMBL29818731 | 0.86 | GAA (0.64) | SALL4SYKGAAKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1901748-B1 | ANGIOGENESIS INHIBITORS | ONCALIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| EP-1901748-B1 | ANGIOGENESIS INHIBITORS | ONCALIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| EP-1765351-B9 | PROTEIN KINASE INHIBITORS | ONCALIS AG (CH) | 2010-03-24 | — | — | EP | disclosed |
| EP-1765351-B9 | PROTEIN KINASE INHIBITORS | ONCALIS AG (CH) | 2010-03-24 | — | — | EP | disclosed |
| EP-1765351-B1 | PROTEIN KINASE INHIBITORS | ONCALIS AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| EP-1765351-B1 | PROTEIN KINASE INHIBITORS | ONCALIS AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-20070149535-A1 | Protein kinase inhibitors | ONCALIS AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-20070149535-A1 | Protein kinase inhibitors | ONCALIS AG (CH) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149535-A1 | Protein kinase inhibitors | FLT1, ERBB2, ERBB3 | SALL4 2422/4885SYK 469/4885GAA 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.